NCT05870917
A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia
At risk: Primary endpoint(s) modified.
See at-risk trials from Institute of Hematology & Blood Diseases Hospital, China
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary endpoint(s) modified Show 6 more changesShow less
- Eligibility criteria expanded, about 45 words
- Final enrollment: 25 participants (planned 20)
- Primary completion date changed from estimate of Jun 2026 to Sep 18, 2025
- Interventions modified
- Secondary endpoints: 4 to 5
- Study description shortened, about 2 words
- Minor Trial status changed: Recruiting → Active, Not Recruiting
- Start date: Apr 25, 2023 to May 23, 2023
- Site details revised
- Notable Primary completion date: Apr 2025 to Jun 2026v3
- Minor Study description shortened, about 20 words
- Study title shortened, about 1 word
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (5)
Arms and interventions
VRD:Bortezomib, Lenalidomide and Dexamethasone Bortezomib SC 1.3mg/sqm on day 1,8,15,22, Lenalidomide oral 25 mg on day 1-21, and Dexamethasone 40mg on day 1,8,15,22 in a 28-day cycle. Autologous BCMA-directed CAR T cells: two sequential intravenous infusions of the same product in each patient, either YK-BB-002 at a target dose of (2-4) × 10⁶ ± 20% CAR-positive T cells/kg or equecabtagene autoleucel at a planned dose of 1.0 × 10⁶ CAR-positive T cells/kg. Participants will receive VRD-based induction, first CAR-T infusion, VR-based consolidation, ASCT followed by the second CAR-T infusion, and R-based maintenance.
Biologicals: anti-BCMA CAR-T
Drugs: VRD-based Regimen
Sites
1 site in 1 country
- Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical SciencesTianjin, China